Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

69.24 -0.48 (-0.69%)
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Celcuity Stock Was a Winner on Wednesday ↗
Its first commercialized drug is now available for qualified patients. 
Via The Motley Fool
News headline image
Celcuity (CELC) Q2 2026 Earnings Call Transcript ↗
Revtopik launch underway with 80 oncology specialists supporting expansion into first-line treatment. 
Via The Motley Fool
Topics Earnings
News headline image
Celcuity Q2 Earnings Call Highlights ↗
Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026... 
Via MarketBeat
Topics Earnings
Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus ↗
Via Chartmill
Topics Earnings
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib ↗
Via Chartmill
Topics Earnings
News headline image
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript ↗
On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call... 
Via Benzinga
Topics Earnings
News headline image
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer ↗
Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the... 
Via MarketBeat
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline. 
Via The Motley Fool
News headline image
Celcuity Q1 Earnings Call Highlights ↗
Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its... 
Via MarketBeat
Topics Earnings
News headline image
Celcuity (CELC) Q1 2026 Earnings Transcript ↗
Celcuity (CELC) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
Via The Motley Fool
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Why Celcuity Stock Popped on Monday ↗
An analyst initiated coverage of the biotech. 
Via The Motley Fool
News headline image
Why Celcuity Stock Popped Today ↗
The cancer-focused biotech published its final set of figures for 2025. 
Via The Motley Fool
News headline image
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals. 
Via The Motley Fool
News headline image
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Closes Position in GEO Stock, Sells $17.6 Million Worth of Shares, According to Recent SEC Filing ↗
This corrections firm delivers facility management and reentry services to government clients in the U.S., Australia, and South Africa. 
Via The Motley Fool
Topics Immigration Regulatory Compliance
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.